GentiBio will use their proprietary regulatory T cell platform to develop the engineered therapies against multiple targets.
The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Review top news and interview highlights from the week ending August 12, 2022.
The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.
AstroRx previously demonstrated clinically meaningful reductions in the rate of disease progression.
Nula-cel is intended to directly correct the mutation that causes sickle cell disease.